A surrogate ELISA to select high titer human convalescent plasma for treating immunocompromised patients infected with SARS-CoV-2 variants of concern
J Infect Dis. 2025 Jan 3:jiae645. doi: 10.1093/infdis/jiae645. Online ahead of print.
PMID:
Targets of influenza human T-cell response are mostly conserved in H5N1
mBio. 2025 Feb 5;16(2):e0347924. doi: 10.1128/mbio.03479-24. Epub 2024 Dec 23.
PMID:
A single immunization with intranasal Newcastle disease virus (NDV)-based XBB.1.5 variant vaccine reduces disease and transmission in animals against matched-variant challenge
Vaccine. 2025 Jan 25;45:126586. doi: 10.1016/j.vaccine.2024.126586. Epub 2024 Dec 12.
PMID:
Tick-Borne Encephalitis Virus Surveillance-Vaccination- and Infection-Induced Seroprevalences in Western Austria 2024
J Med Virol. 2024 Dec;96(12):e70109. doi: 10.1002/jmv.70109.
PMID:
Long-term effectiveness of an ultra-rapid rollout vaccination campaign with BNT162b2 on the incidence of SARS-CoV-2 infection
iScience. 2024 Oct 10;27(11):111117. doi: 10.1016/j.isci.2024.111117. eCollection 2024 Nov 15.
PMID:
Preclinical evaluation of a universal inactivated influenza B vaccine based on the mosaic hemagglutinin-approach
NPJ Vaccines. 2024 Nov 17;9(1):222. doi: 10.1038/s41541-024-01014-8.
PMID:
Proteomic signatures of vaccine-induced and breakthrough infection-induced host responses to SARS-CoV-2
Vaccine. 2025 Jan 1;43(Pt 1):126484. doi: 10.1016/j.vaccine.2024.126484. Epub 2024 Nov 8.
PMID:
Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccination
Cell Rep. 2024 Nov 26;43(11):114922. doi: 10.1016/j.celrep.2024.114922. Epub 2024 Nov 5.
PMID:
Pre-existing H1N1 immunity reduces severe disease with bovine H5N1 influenza virus
bioRxiv [Preprint]. 2024 Oct 23:2024.10.23.619881. doi: 10.1101/2024.10.23.619881.
PMID:
EQUAL ABPA Score 2024: A Tool to Measure Guideline Adherence for Managing Allergic Bronchopulmonary Aspergillosis
Mycoses. 2024 Oct;67(10):e13810. doi: 10.1111/myc.13810.
PMID: